Veradermics, Inc (MANE)
Veradermics develops VDPHL01, an oral, non-hormonal treatment for hair loss, from its base in New Haven, Connecticut. It last closed at $125.89 on Nov 17, down 1.69% on the day. The average 12-month price target from 4 analysts is $175.25 (+39.2% from the last close), with a high of $204.00 and a low of $150.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $1.8M, the largest $1.2M.
Key Stats
Last 12 monthsNot reported for this period.
From MANE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on MANE in the past 90 days. The average target is $175.25, with a high of $204.00 and a low of $150.00, compared with the last close of $125.89.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 10 | Citigroup | Target raised | Buy | $160 → $175 |
| Nov 9 | Leerink Partners | Maintained | Buy | $150 |
| Oct 22 | B. Riley Securities | Target raised | Buy | $170 → $204 |
| Oct 19 | Needham | Target raised | Buy | $164 → $172 |
| Jul 16 | Citigroup | Target raised | Buy | $135 → $160 |
Technical Analysis
The stock sits between its 20 and 50 day averages. Momentum is fading (RSI 46). The nearest support is the swing low (Nov 5) at $125.40, and the nearest resistance the Pivot at $126.73.
| RSI (14) | 45.84 | Middle of its range | Neutral |
| MACD | 2.67 | Below its signal line | Bearish |
| Stochastic | 8.8 | Near the bottom of its range | Oversold |
| ADX (14) | 22.3 | Weak trend | |
| Williams %R | -95.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -151.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −5.5% | Change over 10 sessions | Bearish |
| ATR (14) | $9.29 | Typical daily range, 7.4% of price |
| RSI (14) | 58.58 | Middle of its range | Neutral |
| MACD | 13.38 | Above its signal line | Bullish |
| Stochastic | 64.3 | Middle of its range | Neutral |
| ADX (14) | 45.7 | Strong uptrend | |
| Williams %R | -49.0 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 69.0 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +27.2% | Change over 10 sessions | Bullish |
| ATR (14) | $16.21 | Typical daily range, 12.9% of price |
What happened before
See how MANE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in MANE in the last 90 days.
Dark Pool
30DMANE Institutional Ownership
Full report →- ▲136 buying vs 70 selling
- ▲Held by funds +5.5 pts
- ▲Funds holding +43
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 208 | 165 | +26.1% |
| In funds' top 10 | 6 | 8 | −25.0% |
| Held by funds | 86.3% | 80.8% | +5.5 pts |
| New / increased | 60 / 76 | 95 / 42 | −0.7% |
| Reduced / sold out | 53 / 17 | 19 / 14 | +112.1% |
| Put/call ratio | 0.73 | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MANE is in one of them and how their past MANE trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MANE in an article yet. Here's the latest on the wider market.
About Veradermics
Veradermics is a biopharmaceutical company based in New Haven, Connecticut, that is developing treatments for hair loss. Its main product in development, VDPHL01, is an oral, extended-release form of minoxidil, a drug already used to grow hair, and it is designed to be non-hormonal. The company is running clinical trials in men and women with this condition and does not yet have an approved product. Its target customers are patients with hair loss and the dermatologists who treat them.
- Headquarters
- New Haven, CT


